Saturday, November 02, 2019 8:22:58 AM
Gene Biotherapeutics Inc., formerly Taxus Cardium Pharmaceuticals Group Inc., is engaged in managing a medical technologies portfolio of equity-based and potential royalty-driven investments. The Company's portfolio includes Angionetics, Inc. (Angionetics); Activation Therapeutics, Inc. (Activation Therapeutics); LifeAgain Insurance Solutions, Inc. (LifeAgain), and a minority investment in Healthy Brands Collective. Angionetics is its subsidiary focused on late-stage clinical development and commercialization of Generx, which is an angiogenic gene therapy product candidate designed for medical revascularization for treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. Activation Therapeutics is its subsidiary focused on development and commercialization of Excellagen technology platform, which is a flowable dermal matrix for wound care that has application as a delivery platform for small molecule drugs, proteins and biologics.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM